ICCM — IceCure Medical Ltd

IceCure Medical (ICCM) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $2.1 million for the first nine months of 2025, down from $2.4 million in the same period in 2024. The decline was attributed to reduced sales in Japan and other territories, partially offset by increased sales in Latin America.
• Gross Profit: $626,000, up from $134,000 year-over-year, resulting in a gross margin of 30% compared to 43% in 2024.
• Operating Expenses: Decreased to $11.5 million from $12.2 million, reflecting cost optimization efforts.
• Net Loss: $10.8 million, or $0.18 per share, compared to a net loss of $10 million, or $0.22 per share, in the prior year.
• Cash Position: $10 million in cash and equivalents as of September 30, 2025, up from $7.6 million at the end of 2024, bolstered by a successful rights offering that raised $10 million.

2. Strategic Updates and Business Highlights

• FDA Authorization: Significant milestone achieved with FDA marketing authorization for the ProSense system to treat low-risk breast cancer in women aged 70 and older, expanding the addressable market to approximately 200,000 patients annually.
• Commercial Expansion: Over 20 commercial sites using ProSense prior to FDA approval, with plans to increase installations and utilization. A post-market study is planned with 30 clinical sites.
• International Interest: Growing global interest in ProSense, with recent approvals in Switzerland and ongoing discussions with a Brazilian medical delegation.
• Innovation: Continued progress on new product development and intellectual property, including a recent patent allowance in the U.S. and Japan.

3. Forward Guidance and Outlook

• The company anticipates fluctuations in revenue as commercial activities ramp up following FDA clearance.
• Expected increase in CPT reimbursement rates in January 2026, which should enhance patient access.
• Plans to submit a regulatory application in Japan in the first half of 2026, expanding market access.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Year-over-year revenue decline raises concerns about market traction and sales execution in certain regions.
• Gross Margin Pressure: A decrease in gross margin from the previous year may indicate challenges in cost management or pricing pressures.
• Regulatory Risks: Awaiting final approval for the post-market study protocol from the FDA, which could delay patient recruitment and further commercialization efforts.

5. Notable Q&A Insights

• Management confirmed ongoing communication with the FDA regarding the post-market study, with expectations for final approval by early 2026.
• Clarification on the expanded patient population eligible for cryoablation, including an additional 88,000 patients who are not surgical candidates and 63,000 patients with benign tumors, enhancing the addressable market significantly.
• Management expressed confidence in the growth trajectory post-FDA authorization, emphasizing the strategic importance of their commercialization efforts in the U.S. and globally.

This summary encapsulates the key elements from the earnings call, providing a balanced view of IceCure Medical's current performance and future outlook.